Endocrinology

Stay updated with the latest healthcare breakthroughs, including topline phase 2 data, FDA actions, and regulatory submissions, in this week’s essential news roundup.

This secondary analysis of the phase 3b SOUL cardiovascular outcomes trial indicates oral semaglutide’s potential capacity to reduce HF events.

These data from the ongoing VESPER-3 phase 2b study highlight PF’3944’s capacity for reducing weight across 4 weekly-monthly dosing arms.

Catch up with major trial results, key FDA approvals, and more.

Since 1990, the prevalence of individuals with a BMI ≥30 has increased dramatically, and without significant intervention, will continue to do so.

The US Centers for Medicare & Medicaid Services selected 15 high-cost drugs for the third cycle of the Medicare Drug Price Negotiation Program, including the first-ever Part B drugs.

Frikke-Schmidt discusses the newfound genetic correlation between vascular-related dementia and an increased BMI, partially mediated by high blood pressure.

The investigational dual GLP-1/GIP receptor agonist resulted in substantial weight loss without plateau after 48 weeks in patients with obesity.

MannKind Therapeutics has announced new starting dose recommendations for patients with type 1 diabetes switching from injected or insulin pump mealtime therapy.

Lund highlights the value of preventive treatment in patients with prediabetes on the environment via reduced greenhouse gas emissions.

Fonseca explains the structure and goals of the ongoing trial, which has enrolled its first patient to clofutriben treatment against hard-to-control T2D.

Lund discusses a recent study detailing the comparatively lower greenhouse gas emissions caused by preventive care versus diabetes management.

This segment of Diabetes Dialogue spotlights the FDA clearance of the MiniMed Go and its collaborative capacity with various other devices.

This segment of Diabetes Dialogue spotlights the recent announcement of a partnership between Diabeloop and Sequel Med Tech.

This segment of Diabetes Dialogue spotlights the new guidelines’ broad suggestion regarding alcohol, as well as how organizations may interpret it.

Weintraub discusses how patients with overweight or obesity, regardless of T2D, will regain weight in varying degrees after discontinuing therapy.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clearances, in this week’s essential news roundup.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review tech updates from Sequel Med Tech, Diabeloop, and Medtronic.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Susan Weiner, MS, to discuss the recently released US Dietary Guidelines.

Manne-Goehler discusses a recent study highlighting the scope and scale at which GLP-1 receptor agonists can reduce obesity and its associated risks.

An FDA review found no increased risk of SI/B associated with the use of GLP-1 RA medications, including liraglutide, semaglutide, and tirzepatide.

These recommendations simultaneously emphasize the efficacy of weight loss drugs and encourage incorporating lifestyle therapy on top of medication.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

According to an announcement by parent company Medtronic, the MiniMed Go app is expected to launch in the spring of 2026.